NYSE American New 52-Week Highs And Lows
BiomX Announces a Mandatory Unit Separation
BiomX Inc (PHGE) Q2 2024 Earnings Call Highlights: Strong Financial Turnaround and Promising ...
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024
HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $2 Price Target
Earnings Call: BiomX Reports Q2 2024 Financials, Clinical Updates
BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript Summary
BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript
BiomX 2Q Net $4.5M >PHGE
BiomX 2Q EPS 7c >PHGE
BiomX Q2 EPS $(0.07) Up From $(0.12) YoY; Cash Balance, Short-term Deposits And Restricted Cash As Of June 30, 2024, Were $32.7M, Sufficient To Fund Its Operations Through The Fourth Quarter Of 2025
BiomX Announced A One-for-ten Reverse Split, Effective August 26
BiomX Q2 GAAP EPS $(0.07) Up From $(0.12) YoY
10-Q:Q2 2024 四半期報告書
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
Top 3 Health Care Stocks That May Explode In Q3
BiomX Plan to Regain Compliance Accepted by NYSE American
Cystic Fibrosis Market Is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech, Aridis Pharmaceuticals, BiomX, Inc., Boehringer Ingelheim
12 Health Care Stocks Moving In Tuesday's After-Market Session
データなし
データなし